HRP20160108T1 - Uporaba testosterona i 5-ht1a agonista u tretiranju seksualne disfunkcije - Google Patents
Uporaba testosterona i 5-ht1a agonista u tretiranju seksualne disfunkcije Download PDFInfo
- Publication number
- HRP20160108T1 HRP20160108T1 HRP20160108T HRP20160108T HRP20160108T1 HR P20160108 T1 HRP20160108 T1 HR P20160108T1 HR P20160108 T HRP20160108 T HR P20160108T HR P20160108 T HRP20160108 T HR P20160108T HR P20160108 T1 HRP20160108 T1 HR P20160108T1
- Authority
- HR
- Croatia
- Prior art keywords
- testosterone
- metabolite
- precursor
- ht1a agonist
- ht1a
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims 46
- 239000003723 serotonin 1A agonist Substances 0.000 title claims 23
- 229960003604 testosterone Drugs 0.000 title claims 23
- 201000001880 Sexual dysfunction Diseases 0.000 title claims 5
- 231100000872 sexual dysfunction Toxicity 0.000 title claims 5
- 239000002207 metabolite Substances 0.000 claims 22
- 239000002243 precursor Substances 0.000 claims 22
- -1 Eptapiron Chemical compound 0.000 claims 7
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 7
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 3
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 2
- 229960002495 buspirone Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- IPRJDKMLMDPMBH-XFULWGLBSA-N (3r)-n-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-[1]benzothiolo[2,3-c]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.S1C2=CC=CC=C2C(C2)=C1CN[C@H]2C(=O)NCC1=CC=C(OCO2)C2=C1 IPRJDKMLMDPMBH-XFULWGLBSA-N 0.000 claims 1
- UXWBIYCPUVWKHP-KBPBESRZSA-N 1-[[(7s,9as)-2-pyrimidin-2-yl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-yl]methyl]pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1C[C@@H]1CN2CCN(C=3N=CC=CN=3)C[C@@H]2CC1 UXWBIYCPUVWKHP-KBPBESRZSA-N 0.000 claims 1
- LYXKFNHUJJDTIA-UHFFFAOYSA-N 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,1-dioxo-1,2-benzothiazol-3-one Chemical compound O=C1C2=CC=CC=C2S(=O)(=O)N1CCCCN(CC1)CCN1C1=CC(Cl)=CC2=C1OCCO2 LYXKFNHUJJDTIA-UHFFFAOYSA-N 0.000 claims 1
- DPXOFRGRKPFZOD-UHFFFAOYSA-N 3-[2-(dipropylamino)ethyl]-1H-indole-5-carboxamide Chemical compound C1=C(C(N)=O)C=C2C(CCN(CCC)CCC)=CNC2=C1 DPXOFRGRKPFZOD-UHFFFAOYSA-N 0.000 claims 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical group C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 claims 1
- QYFHCFNBYQZGKW-BDQAORGHSA-N 8-[4-[[(3s)-5-methoxy-3,4-dihydro-2h-chromen-3-yl]-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione;hydrochloride Chemical compound Cl.CCCN([C@H]1CC2=C(OC)C=CC=C2OC1)CCCCN(C(C1)=O)C(=O)CC21CCCC2 QYFHCFNBYQZGKW-BDQAORGHSA-N 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229950000420 alnespirone Drugs 0.000 claims 1
- 229940015273 buspar Drugs 0.000 claims 1
- UEAKCKJAKUFIQP-OAHLLOKOSA-N ebalzotan Chemical compound C1=CC(C(=O)NC(C)C)=C2C[C@@H](N(C(C)C)CCC)COC2=C1 UEAKCKJAKUFIQP-OAHLLOKOSA-N 0.000 claims 1
- 229950007357 ebalzotan Drugs 0.000 claims 1
- NYSDRDDQELAVKP-SFHVURJKSA-N flesinoxan Chemical compound C([C@@H](O1)CO)OC2=C1C=CC=C2N(CC1)CCN1CCNC(=O)C1=CC=C(F)C=C1 NYSDRDDQELAVKP-SFHVURJKSA-N 0.000 claims 1
- 229950003678 flesinoxan Drugs 0.000 claims 1
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960002053 flibanserin Drugs 0.000 claims 1
- AHCPKWJUALHOPH-UHFFFAOYSA-N lesopitron Chemical compound C1=C(Cl)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 AHCPKWJUALHOPH-UHFFFAOYSA-N 0.000 claims 1
- 229950001590 lesopitron Drugs 0.000 claims 1
- JITOKQVGRJSHHA-UHFFFAOYSA-M monosodium methyl arsenate Chemical compound [Na+].C[As](O)([O-])=O JITOKQVGRJSHHA-UHFFFAOYSA-M 0.000 claims 1
- MEEQBDCQPIZMLY-HNNXBMFYSA-N osemozotan Chemical compound C1=C2OCOC2=CC(OCCCNC[C@@H]2OC3=CC=CC=C3OC2)=C1 MEEQBDCQPIZMLY-HNNXBMFYSA-N 0.000 claims 1
- URMTUEWUIGOJBW-UHFFFAOYSA-N piclozotan Chemical compound ClC1=COC2=CC=CC=C2C(=O)N1CCCCN(CC=1)CCC=1C1=CC=CC=N1 URMTUEWUIGOJBW-UHFFFAOYSA-N 0.000 claims 1
- YGYBFMRFXNDIPO-QGZVFWFLSA-N repinotan Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCNC[C@@H]1OC2=CC=CC=C2CC1 YGYBFMRFXNDIPO-QGZVFWFLSA-N 0.000 claims 1
- 229950009693 repinotan Drugs 0.000 claims 1
- 229950011106 sunepitron Drugs 0.000 claims 1
- 229960001130 urapidil Drugs 0.000 claims 1
- AERLHOTUXIJQFV-RCPZPFRWSA-N zalospirone Chemical compound O=C([C@@H]1[C@@H]([C@@H]2C=C[C@H]1[C@H]1C=C[C@H]12)C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 AERLHOTUXIJQFV-RCPZPFRWSA-N 0.000 claims 1
- 229950005255 zalospirone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Claims (10)
1. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu u tretiranju seksualne disfunkcije, naznačeno time da se spomenuti 5-HT1A agonist u suštini otpušta između jednog sata i 1,5 sati prije početka i spomenuti testosteron ili metabolit ili njihov prekursor 3,5-5,5 sati prije seksualne aktivnosti tako da se vrhunac učinaka 5-HT1A agonista i testosterona ili metabolita ili njihovog prekursora djelomično preklapaju.
2. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu prema patentnom zahtjevu 1, nadalje obuhvaća PDE5 inhibitor za uporabu u tretiranju seksualne disfunkcije, naznačeno time da se spomenuti 5-HT1A u suštini otpušta između jednog sata i 1,5 sati prije početka, spomenuti PDE5 inhibitor 1-2 sati i spomenuti testosteron ili metabolit ili njihov prekursor 3,5-5,5 sati prije seksualne aktivnosti tako da se vrhunac učinaka 5-HT1A agonista, PDE5 inhibitora i testosterona ili metabolita ili njihovog prekursora djelomično preklapaju.
3. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu prema patentnom zahtjevu 1, naznačeno time da su spomenuti testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist obezbijeđeni kao farmaceutski pripravak koji obuhvaća testosteron ili metabolit ili njihov prekursor i 5- HT1A agonist.
4. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu prema patentnom zahtjevu 2, naznačeno time da su spomenuti testosteron ili metabolit ili njihov prekursor, 5-HT1A agonist, i PDE5 inhibitor obezbijeđeni kao farmaceutski pripravak koji obuhvaća testosteron ili metabolit ili njihov prekursor, PDE5 inhibitor i 5-HT1A agonist.
5. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu prema patentnom zahtjevu 1, naznačeno time da su spomenuti testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist obezbijeđeni kao komplet dijelova koji obuhvaća najmanje jedan farmaceutski pripravak koji obuhvaća testosteron ili metabolit ili njihov prekursor koji obuhvaća 5-HT1A agonist.
6. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu prema patentnom zahtjevu 2, naznačeno time da su spomenuti testosteron ili metabolit ili njihov prekursor, 5-HT1A agonist i PDE5 inhibitor obezbijeđeni kao komplet dijelova koji obuhvaća najmanje jedan farmaceutski pripravak koji obuhvaća testosteron ili metabolit ili njihov prekursor, najmanje jedan pripravak koji obuhvaća PDE5 inhibitor i najmanje jedan pripravak koji obuhvaća 5-HT1A agonist.
7. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačeno time da je spomenuta seksualna disfunkcija ženska seksualna disfunkcija.
8. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačeno time da je spomenuta seksualna disfunkcija muška seksualna disfunkcija.
9. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu prema bilo kojem od patentnih zahtjeva 1-8, naznačeno time da je 5-HT1A agonist 8-OH- DPAT, Alnespiron, AP-521, Buspar, Buspiron, Dipropil-5-CT, DU-125530, E6265, Ebalzotan, Eptapiron, Flesinoxan, Flibanserin, Gepiron, Ipsapiron, Lesopitron, LY293284, LY301317, MKC242, R(+)-ZTH-301, Repinotan, SR57746A, Sunepitron, SUN-N4057, Tandosporin, U-92016A, Urapidil, VML-670, Zalospiron ili Zaprasidon.
10. Testosteron ili metabolit ili njihov prekursor i 5-HT1A agonist za uporabu prema patentnom zahtjevu 9, naznačeno time da je 5-HT1A agonist buspiron.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076976A EP1925307A1 (en) | 2006-11-03 | 2006-11-03 | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| PCT/NL2007/050533 WO2008054213A2 (en) | 2006-11-03 | 2007-11-02 | Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction |
| EP07834663.2A EP2086544B1 (en) | 2006-11-03 | 2007-11-02 | Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160108T1 true HRP20160108T1 (hr) | 2016-03-25 |
Family
ID=37846101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160108T HRP20160108T1 (hr) | 2006-11-03 | 2016-02-01 | Uporaba testosterona i 5-ht1a agonista u tretiranju seksualne disfunkcije |
Country Status (28)
| Country | Link |
|---|---|
| US (10) | US8653051B2 (hr) |
| EP (5) | EP1925307A1 (hr) |
| JP (8) | JP2010509211A (hr) |
| KR (6) | KR20090115113A (hr) |
| CN (6) | CN104524580A (hr) |
| AU (3) | AU2007314735B2 (hr) |
| BR (3) | BRPI0717963A2 (hr) |
| CA (3) | CA2668317C (hr) |
| CY (1) | CY1117191T1 (hr) |
| DK (1) | DK2086544T3 (hr) |
| ES (1) | ES2561946T3 (hr) |
| HK (1) | HK1135038A1 (hr) |
| HR (1) | HRP20160108T1 (hr) |
| HU (1) | HUE026752T2 (hr) |
| IL (5) | IL198460A (hr) |
| ME (1) | ME02410B (hr) |
| MX (3) | MX2009004696A (hr) |
| NO (3) | NO343597B1 (hr) |
| NZ (3) | NZ577390A (hr) |
| PH (2) | PH12014501440A1 (hr) |
| PL (1) | PL2086544T3 (hr) |
| PT (1) | PT2086544E (hr) |
| RS (1) | RS54541B1 (hr) |
| RU (4) | RU2491073C2 (hr) |
| SI (1) | SI2086544T1 (hr) |
| UA (4) | UA103592C2 (hr) |
| WO (3) | WO2008054215A2 (hr) |
| ZA (3) | ZA200903835B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2436579C2 (ru) | 2004-05-11 | 2011-12-20 | Эмоушнл Брэйн Б.В. | Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| KR102158948B1 (ko) * | 2011-05-13 | 2020-09-24 | 이비 아이피 하이브리탭스 비.브이. | 약물 전달 시스템 |
| HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| JP5828923B2 (ja) | 2014-01-30 | 2015-12-09 | 国立大学法人高知大学 | ニッケル粉の製造方法 |
| US10471514B2 (en) | 2014-02-21 | 2019-11-12 | Kochi University, National University Corporation | Method for producing nickel powder |
| JP6406613B2 (ja) | 2014-04-15 | 2018-10-17 | 住友金属鉱山株式会社 | 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法 |
| CN103947533B (zh) * | 2014-05-15 | 2015-12-16 | 青岛理工大学 | 生长环境可控的磁化水工厂化豆芽菜生产系统 |
| RU2600845C2 (ru) | 2014-07-04 | 2016-10-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3251436A (en) * | 1965-03-16 | 1966-05-17 | Dayton Steel Foundry Co | Spot-type disk brake |
| US3976776A (en) * | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| DK169601B1 (da) * | 1983-10-17 | 1994-12-19 | Duphar Int Res | Piperazinderivater og farmaceutisk præparat indeholdende et sådant derivat, samt piperazinderivater med mellemproduktanvendelse |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US5015646A (en) * | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
| US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| CA1335106C (en) * | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
| US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| RU2152787C2 (ru) | 1994-06-02 | 2000-07-20 | Дан Рига | Лекарство против стресса, против снижения уровня активности и против старения и способ его получения |
| US6174890B1 (en) | 1994-06-02 | 2001-01-16 | Dan Riga | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
| US5698560A (en) | 1995-03-01 | 1997-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
| CZ278497A3 (cs) | 1995-03-14 | 1998-04-15 | Vivus, Incorporated | Způsob a sestava zařízení k prevenci impotence |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| CA2219082A1 (en) | 1995-05-15 | 1996-11-21 | Beth Israel Deaconess Medical Center, Inc. | Use of dihydrotestosterone compounds for treating male sexual dysfunction |
| GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6251436B1 (en) * | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US6242198B1 (en) | 1996-07-25 | 2001-06-05 | Cambridge Neuroscience, Inc. | Methods of treatment of eye trauma and disorders |
| AU756136B2 (en) * | 1997-06-23 | 2003-01-02 | Queen's University At Kingston | Microdose therapy |
| US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| JP2001520999A (ja) | 1997-10-28 | 2001-11-06 | アシビ， エルエルシー | 女性の性的機能不全の処置 |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| US6246436B1 (en) * | 1997-11-03 | 2001-06-12 | Agilent Technologies, Inc | Adjustable gain active pixel sensor |
| TW542719B (en) * | 1998-02-23 | 2003-07-21 | Pfizer Res & Dev | Method of treating impotence due to spinal cord injury |
| US6403605B1 (en) * | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
| EP1173167A4 (en) | 1999-04-30 | 2004-07-14 | Lilly Icos Llc | TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS |
| US6632419B2 (en) * | 1999-05-04 | 2003-10-14 | Aradigm Corporation | Increasing libido in humans via acute testosterone administration |
| US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
| US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
| CA2377339A1 (en) | 1999-06-17 | 2000-12-28 | Armin Johannes Becker | Administration of growth hormone (hgh) for the therapy of sexual functional disorders |
| RU2180591C2 (ru) | 1999-12-24 | 2002-03-20 | Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ | Средство для лечения сексуальных дисфункций у мужчин |
| DE10016548A1 (de) * | 2000-04-03 | 2001-10-11 | Bayer Ag | Polyurethan-Dispersionen |
| US6313172B1 (en) | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US6242436B1 (en) * | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| CN1473047A (zh) | 2000-08-30 | 2004-02-04 | ������ҩ������˾ | 治疗男性勃起功能障碍和增强性冲动的方法 |
| US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| SK287066B6 (sk) | 2000-09-29 | 2009-11-05 | Solvay Pharmaceuticals B. V. | Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy |
| US20060287335A1 (en) * | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
| JP2004522720A (ja) * | 2000-12-15 | 2004-07-29 | ファイザー・インク | 雄性性的機能障害の処置 |
| US20020107230A1 (en) | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| EP1383502A4 (en) | 2001-03-06 | 2007-07-25 | Strakan Int Ltd | COMPOUNDS AND METHOD FOR TREATING UROGENITAL DISORDER |
| EA006154B1 (ru) | 2001-03-28 | 2005-10-27 | Пфайзер Инк. | N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad |
| EP1260225A1 (en) * | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| US20030027804A1 (en) | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20030022875A1 (en) * | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| JP2007516949A (ja) * | 2003-07-16 | 2007-06-28 | ファイザー・インク | 性機能不全の治療 |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| ES2258694T3 (es) * | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| WO2005094827A1 (en) * | 2004-03-30 | 2005-10-13 | Kestrel Pharmaceuticals Inc. | Methods for treating sexual dysfunction |
| RU2445095C2 (ru) | 2004-04-22 | 2012-03-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые фармацевтические композиции для лечения сексуальных расстройств |
| RU2436579C2 (ru) * | 2004-05-11 | 2011-12-20 | Эмоушнл Брэйн Б.В. | Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции |
| KR20080016552A (ko) * | 2005-04-13 | 2008-02-21 | 유니메드 파마슈티칼스, 인크. | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 |
| WO2006127057A1 (en) * | 2005-05-24 | 2006-11-30 | Lyle Corporate Drvelopment, Inc. | Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction |
| WO2006125642A1 (en) * | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| WO2007054791A2 (en) | 2005-11-08 | 2007-05-18 | L'oréal | Androgen glucuronides as markers of androgenic activity |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| KR101694551B1 (ko) | 2007-11-28 | 2017-01-09 | 유씨비 파마 게엠베하 | 로티고틴의 다형 형태 |
-
2006
- 2006-11-03 EP EP06076976A patent/EP1925307A1/en not_active Ceased
-
2007
- 2007-02-11 UA UAA200905653A patent/UA103592C2/uk unknown
- 2007-02-11 UA UAA200905654A patent/UA101948C2/uk unknown
- 2007-02-11 ME MEP-2016-33A patent/ME02410B/me unknown
- 2007-02-11 UA UAA200905652A patent/UA100119C2/uk unknown
- 2007-11-02 EP EP07834664A patent/EP2086545A2/en not_active Withdrawn
- 2007-11-02 KR KR1020097011485A patent/KR20090115113A/ko not_active Application Discontinuation
- 2007-11-02 AU AU2007314735A patent/AU2007314735B2/en not_active Ceased
- 2007-11-02 ZA ZA200903835A patent/ZA200903835B/xx unknown
- 2007-11-02 CN CN201410844093.6A patent/CN104524580A/zh active Pending
- 2007-11-02 AU AU2007314736A patent/AU2007314736B2/en not_active Ceased
- 2007-11-02 KR KR1020157022168A patent/KR20150099620A/ko active Application Filing
- 2007-11-02 RS RS20160069A patent/RS54541B1/en unknown
- 2007-11-02 PT PT78346632T patent/PT2086544E/pt unknown
- 2007-11-02 ZA ZA200903837A patent/ZA200903837B/xx unknown
- 2007-11-02 NZ NZ577390A patent/NZ577390A/xx not_active IP Right Cessation
- 2007-11-02 HU HUE07834663A patent/HUE026752T2/en unknown
- 2007-11-02 BR BRPI0717963-4A2A patent/BRPI0717963A2/pt not_active IP Right Cessation
- 2007-11-02 JP JP2009535226A patent/JP2010509211A/ja not_active Withdrawn
- 2007-11-02 EP EP15167346.4A patent/EP2937086A1/en not_active Withdrawn
- 2007-11-02 EP EP07834665A patent/EP2086548A2/en not_active Withdrawn
- 2007-11-02 CN CN2007800474487A patent/CN101563086B/zh not_active Expired - Fee Related
- 2007-11-02 EP EP07834663.2A patent/EP2086544B1/en active Active
- 2007-11-02 CN CNA2007800462422A patent/CN101557812A/zh active Pending
- 2007-11-02 WO PCT/NL2007/050535 patent/WO2008054215A2/en active Application Filing
- 2007-11-02 CN CNA2007800491317A patent/CN101573119A/zh active Pending
- 2007-11-02 WO PCT/NL2007/050534 patent/WO2008054214A2/en active Application Filing
- 2007-11-02 ES ES07834663.2T patent/ES2561946T3/es active Active
- 2007-11-02 RU RU2009120992/15A patent/RU2491073C2/ru not_active IP Right Cessation
- 2007-11-02 NZ NZ577393A patent/NZ577393A/xx not_active IP Right Cessation
- 2007-11-02 CA CA2668317A patent/CA2668317C/en not_active Expired - Fee Related
- 2007-11-02 PL PL07834663T patent/PL2086544T3/pl unknown
- 2007-11-02 RU RU2009120990/15A patent/RU2463054C2/ru not_active IP Right Cessation
- 2007-11-02 MX MX2009004696A patent/MX2009004696A/es not_active Application Discontinuation
- 2007-11-02 CN CN201310556256.6A patent/CN103599536A/zh active Pending
- 2007-11-02 CA CA2668320A patent/CA2668320C/en not_active Expired - Fee Related
- 2007-11-02 NZ NZ577392A patent/NZ577392A/xx not_active IP Right Cessation
- 2007-11-02 KR KR1020167028902A patent/KR101796887B1/ko active IP Right Grant
- 2007-11-02 US US12/513,355 patent/US8653051B2/en active Active
- 2007-11-02 KR KR1020097011486A patent/KR20090111803A/ko active Application Filing
- 2007-11-02 BR BRPI0718396-8A2A patent/BRPI0718396A2/pt not_active IP Right Cessation
- 2007-11-02 BR BRPI0717856-5A2A patent/BRPI0717856A2/pt active Search and Examination
- 2007-11-02 UA UAA201214342A patent/UA115647C2/uk unknown
- 2007-11-02 KR KR1020097011483A patent/KR101578224B1/ko active IP Right Grant
- 2007-11-02 MX MX2009004693A patent/MX2009004693A/es active IP Right Grant
- 2007-11-02 WO PCT/NL2007/050533 patent/WO2008054213A2/en active Application Filing
- 2007-11-02 JP JP2009535228A patent/JP2010509213A/ja active Pending
- 2007-11-02 CA CA2668316A patent/CA2668316C/en active Active
- 2007-11-02 US US12/513,358 patent/US8575139B2/en active Active
- 2007-11-02 KR KR20157004613A patent/KR20150038251A/ko not_active Application Discontinuation
- 2007-11-02 CN CN2013102891472A patent/CN103381270A/zh active Pending
- 2007-11-02 DK DK07834663.2T patent/DK2086544T3/en active
- 2007-11-02 SI SI200731745T patent/SI2086544T1/sl unknown
- 2007-11-02 ZA ZA200903836A patent/ZA200903836B/xx unknown
- 2007-11-02 RU RU2009120988/15A patent/RU2464027C2/ru not_active IP Right Cessation
- 2007-11-02 JP JP2009535227A patent/JP2010509212A/ja active Pending
- 2007-11-02 AU AU2007314734A patent/AU2007314734B2/en not_active Ceased
- 2007-11-02 US US12/513,357 patent/US8648060B2/en active Active
- 2007-11-02 MX MX2009004695A patent/MX2009004695A/es not_active Application Discontinuation
-
2009
- 2009-04-30 IL IL198460A patent/IL198460A/en active IP Right Grant
- 2009-04-30 IL IL198461A patent/IL198461A/en active IP Right Grant
- 2009-04-30 IL IL198459A patent/IL198459A/en active IP Right Grant
- 2009-06-03 NO NO20092143A patent/NO343597B1/no not_active IP Right Cessation
- 2009-06-03 NO NO20092146A patent/NO20092146L/no not_active Application Discontinuation
- 2009-06-03 NO NO20092145A patent/NO20092145L/no not_active Application Discontinuation
-
2010
- 2010-04-07 HK HK10103442.6A patent/HK1135038A1/xx not_active IP Right Cessation
-
2012
- 2012-06-20 RU RU2012125827A patent/RU2646447C2/ru not_active IP Right Cessation
- 2012-07-10 US US13/545,916 patent/US8669242B2/en active Active
-
2013
- 2013-09-06 JP JP2013185156A patent/JP5748238B2/ja not_active Expired - Fee Related
- 2013-10-08 US US14/049,005 patent/US9211334B2/en not_active Expired - Fee Related
- 2013-10-16 JP JP2013215284A patent/JP2014055142A/ja active Pending
-
2014
- 2014-01-03 US US14/147,393 patent/US20140121189A1/en not_active Abandoned
- 2014-01-03 US US14/147,415 patent/US20140121190A1/en not_active Abandoned
- 2014-01-08 JP JP2014001289A patent/JP2014111608A/ja active Pending
- 2014-06-20 PH PH12014501440A patent/PH12014501440A1/en unknown
- 2014-08-12 PH PH12014501821A patent/PH12014501821B1/en unknown
-
2015
- 2015-03-16 IL IL237786A patent/IL237786A0/en unknown
- 2015-05-07 JP JP2015094573A patent/JP6357131B2/ja not_active Expired - Fee Related
- 2015-12-04 US US14/960,204 patent/US9597335B2/en not_active Expired - Fee Related
-
2016
- 2016-02-01 HR HRP20160108T patent/HRP20160108T1/hr unknown
- 2016-02-12 CY CY20161100116T patent/CY1117191T1/el unknown
- 2016-10-27 IL IL248563A patent/IL248563B/en active IP Right Grant
-
2017
- 2017-02-21 US US15/438,547 patent/US10314848B2/en not_active Expired - Fee Related
- 2017-05-10 JP JP2017093563A patent/JP2017132809A/ja active Pending
-
2019
- 2019-05-14 US US16/412,276 patent/US20190262359A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160108T1 (hr) | Uporaba testosterona i 5-ht1a agonista u tretiranju seksualne disfunkcije | |
| MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
| BRPI0618239A8 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos | |
| RS51569B (en) | COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL | |
| UY28862A1 (es) | Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
| CU20120084A7 (es) | Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación | |
| CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| BRPI0814503A2 (pt) | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica | |
| BR112012007092A2 (pt) | método para a preparação de uma forma cristalina de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-((s)-tetraidrofuran-3-ilóxi)benzil) benzeno | |
| DOP2011000354A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
| CL2008002006A1 (es) | Compuestos derivados de morfolin pirimidina, composicion farmaceutica, y su uso como inhibidores de la m-tor-quinasa para el tratamiento de l a inflamacion, cancer, enfermedades inmunes, enfermedad obstructiva pulmonar, enfermedad cardiovascular. | |
| BRPI0516830A (pt) | composições de droga de liberação sustentada convenientemente implantáveis | |
| BRPI0709057B8 (pt) | veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação | |
| GT200900090A (es) | Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina | |
| JP2014001235A5 (hr) | ||
| ECSP088889A (es) | Forma nueva de administración de racecadotril | |
| BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
| CO6612204A2 (es) | Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina | |
| CL2011002652A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de n-({4-amino-3-[(trihalometil)sulfonil]fenil}sulfonil)-4-(piperazin-1-il)benzamida, un antioxidante calcogeno y un vehiculo lipidico; y su uso para tratar una enfermedad caracterizada por disfuncion apoptotica, tal como una enfermedad neoplasica. | |
| MX2010000266A (es) | Un método para disminuir los síntomas del consumo de alcohol. | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| WO2008116890A3 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| MX2009010989A (es) | Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas. | |
| BR112012009857A8 (pt) | Composições farmacêuticas sólidas contendo um inibidor de integrase | |
| MY142792A (en) | Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases |